chr11-119297446-C-T

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2

The NM_005188.4(CBL):​c.2216C>T​(p.Ser739Phe) variant causes a missense change. The variant allele was found at a frequency of 0.000272 in 1,613,272 control chromosomes in the GnomAD database, including 4 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S739P) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.00014 ( 1 hom., cov: 32)
Exomes 𝑓: 0.00029 ( 3 hom. )

Consequence

CBL
NM_005188.4 missense

Scores

1
7
10

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:9

Conservation

PhyloP100: 4.52

Publications

7 publications found
Variant links:
Genes affected
CBL (HGNC:1541): (Cbl proto-oncogene) This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia, and expansion of CGG repeats in the 5' UTR has been associated with Jacobsen syndrome. Mutations in this gene are also the cause of Noonan syndrome-like disorder. [provided by RefSeq, Jul 2016]
CBL Gene-Disease associations (from GenCC):
  • CBL-related disorder
    Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, ClinGen, G2P, Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Ambry Genetics
  • juvenile myelomonocytic leukemia
    Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
  • Noonan syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.012963235).
BP6
Variant 11-119297446-C-T is Benign according to our data. Variant chr11-119297446-C-T is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 40418.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population sas. GnomAd4 allele frequency = 0.000138 (21/151930) while in subpopulation SAS AF = 0.0021 (10/4768). AF 95% confidence interval is 0.00114. There are 1 homozygotes in GnomAd4. There are 14 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High AC in GnomAd4 at 21 AD gene.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_005188.4. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
CBL
NM_005188.4
MANE Select
c.2216C>Tp.Ser739Phe
missense
Exon 14 of 16NP_005179.2

Ensembl Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
CBL
ENST00000264033.6
TSL:1 MANE Select
c.2216C>Tp.Ser739Phe
missense
Exon 14 of 16ENSP00000264033.3P22681
CBL
ENST00000634586.1
TSL:5
c.2216C>Tp.Ser739Phe
missense
Exon 14 of 18ENSP00000489218.1A0A0U1RQX8
CBL
ENST00000637974.1
TSL:5
c.2210C>Tp.Ser737Phe
missense
Exon 14 of 17ENSP00000490763.1A0A1B0GW38

Frequencies

GnomAD3 genomes
AF:
0.000138
AC:
21
AN:
151812
Hom.:
1
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000242
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000262
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00210
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000883
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.000438
AC:
110
AN:
251278
AF XY:
0.000574
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.000376
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000255
Gnomad OTH exome
AF:
0.000814
GnomAD4 exome
AF:
0.000286
AC:
418
AN:
1461342
Hom.:
3
Cov.:
31
AF XY:
0.000363
AC XY:
264
AN XY:
727000
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33476
American (AMR)
AF:
0.000402
AC:
18
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26134
East Asian (EAS)
AF:
0.0000252
AC:
1
AN:
39700
South Asian (SAS)
AF:
0.00213
AC:
184
AN:
86248
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53146
Middle Eastern (MID)
AF:
0.00156
AC:
9
AN:
5766
European-Non Finnish (NFE)
AF:
0.000163
AC:
181
AN:
1111768
Other (OTH)
AF:
0.000414
AC:
25
AN:
60380
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.482
Heterozygous variant carriers
0
25
51
76
102
127
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000138
AC:
21
AN:
151930
Hom.:
1
Cov.:
32
AF XY:
0.000189
AC XY:
14
AN XY:
74262
show subpopulations
African (AFR)
AF:
0.0000241
AC:
1
AN:
41442
American (AMR)
AF:
0.000262
AC:
4
AN:
15268
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3464
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5164
South Asian (SAS)
AF:
0.00210
AC:
10
AN:
4768
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10592
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.0000883
AC:
6
AN:
67924
Other (OTH)
AF:
0.00
AC:
0
AN:
2104
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.517
Heterozygous variant carriers
0
1
2
4
5
6
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000284
Hom.:
0
Bravo
AF:
0.000162
ExAC
AF:
0.000511
AC:
62
Asia WGS
AF:
0.000289
AC:
1
AN:
3478
EpiCase
AF:
0.000436
EpiControl
AF:
0.000415

ClinVar

ClinVar submissions
Significance:Benign/Likely benign
Revision:criteria provided, multiple submitters, no conflicts
View on ClinVar
Pathogenic
VUS
Benign
Condition
-
-
3
not specified (3)
-
-
2
CBL-related disorder (2)
-
-
2
not provided (2)
-
-
1
Noonan syndrome and Noonan-related syndrome (1)
-
-
1
RASopathy (1)

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.14
BayesDel_addAF
Benign
-0.32
T
BayesDel_noAF
Benign
-0.24
CADD
Uncertain
25
DANN
Benign
0.95
DEOGEN2
Uncertain
0.44
T
Eigen
Benign
0.13
Eigen_PC
Uncertain
0.29
FATHMM_MKL
Pathogenic
0.98
D
LIST_S2
Uncertain
0.93
D
M_CAP
Benign
0.034
D
MetaRNN
Benign
0.013
T
MetaSVM
Benign
-0.42
T
MutationAssessor
Uncertain
2.1
M
PhyloP100
4.5
PrimateAI
Uncertain
0.52
T
PROVEAN
Benign
-0.73
N
REVEL
Benign
0.23
Sift
Uncertain
0.0040
D
Sift4G
Uncertain
0.012
D
Polyphen
0.37
B
Vest4
0.48
MVP
0.90
MPC
0.36
ClinPred
0.028
T
GERP RS
5.3
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Varity_R
0.12
gMVP
0.32
Mutation Taster
=86/14
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.13
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs2227986; hg19: chr11-119168156; COSMIC: COSV50634108; COSMIC: COSV50634108; API
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.